Skip to main content
. 2021 Jun 10;7:137. doi: 10.1038/s41420-021-00496-y

Fig. 4. A therapeutic window was observed in cell proliferation assays with the combination of fadraciclib and AZA.

Fig. 4

A Summary bar charts of flow cytometry data of the percentage of undivided populations of primary AML and D normal hematopoietic patient samples treated with fadraciclib and/or VEN for 72 h. n = 6/3. B Summary bar charts of flow cytometry data of the percentage of undivided populations of primary AML and E normal hematopoietic patient samples treated with fadraciclib and/or AraC for 72 h. n = 6/3. C Summary bar charts of flow cytometry data of the percentage of undivided populations of primary AML and F normal hematopoietic patient samples treated with fadraciclib and/or AZA for 72 h. n = 6/3. Graphs depict mean ± SD (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Data were compared using ANOVA.